OP26 Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab075.025
Abstract: Present therapies leave an unmet need for early and effective treatment for patients with Crohn’s disease (CD). Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody against the p19 subunit of interleukin-23, was evaluated as an… read more here.
Keywords: response; rzb; motivate; patients moderate ... See more keywords
OP36 Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn’s Disease: Results from the phase 3 ADVANCE and MOTIVATE studies
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Crohn's and Colitis"
DOI: 10.1093/ecco-jcc/jjab075.035
Abstract: Endoscopic healing has become a critical treatment target in Crohn’s disease (CD). Risankizumab (RZB), a humanized immunoglobulin G1 monoclonal antibody against the p19 subunit of interleukin 23, is being investigated as a treatment for moderate-to-severe… read more here.
Keywords: response; endoscopic; moderate severe; motivate ... See more keywords